Table 2. Randomized Phase III Immunotherapy Trials
Trial
Na onal clinical
trial iden fier Status
a
PSA-TRICOM ± GM-CSF in
mCPRC
NCT01322490 Completed
± DCVAC added to docetaxel
and prednisone in mCRPC
NCT02111577 Ac ve, not recrui ng; Expected
comple on date June 2019
Valcyclovir ± ProstAtak® as
adjuvant to up-front radia on in
localized pa ents
NCT01436968 Recrui ng; Expected comple on
date December 2020
Sipuleucel-T (Provenge®) NCT01133704 Completed, results available
Sipuleucel-T (Provenge®) NCT00065442 Completed, results available
Ipilimumab NCT00861614 Completed, results available
Ipilimumab NCT01057810 Completed, results available
Sipuleucel-T (Provenge®) NCT00005947 Completed, results available
Valcyclovir ± ProstAtak® (AdV-tk)
as adjuvant to up-front radia on
in localized pa ents
NCT01436968 Recrui ng; Expected comple on
date December 2020
ProstAtak® NCT02768363 Recrui ng; Expected comple on
date December 2018
a
As determined by ClinicalTrials.gov. Accessed March 13, 2018
